

Boston Scientific

Advancing science for life™

Baylis Medical
Company Acquisition
October 6, 2021





Safe Harbor and other disclaimers

Safe harbor for forward-looking statements:

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, the closing of the acquisition, product development and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings "Risk Factors" and "Safe Harbor for Forward-Looking Statements." Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Market Estimates:

Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

Non-GAAP Financial Measures:

This presentation contains non-GAAP measures (denoted with *) in talking about our company's performance. The reconciliations of those non-GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to the end of this presentation.



Regulatory disclaimers


FARAPULSE™ PFA system	CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Millipede mitral repair technology	U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
POLARx™ cryoablation balloon	CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
STABLEPOINT™ force-sensing catheter	CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.



BSX and Baylis Medical Company

**Boston
Scientific**

**Baylis
MEDICAL**





BSX to Acquire Baylis Medical Company

Baylis Medical Overview

- Broad portfolio of cardiac access and therapy delivery solutions
 - A global leader in transseptal needles with innovative radiofrequency devices
- Privately held company founded in 1986
- ~800 employees in acquired business. Headquarters in Ontario, Canada

Deal Terms

- \$1.75B up-front cash purchase price, subject to closing adjustments
 - High single digit ROIC by year 4
- Expected to close in Q1 2022, subject to customary conditions


Shareholder Value

- Immediately accretive to operating income and top-line growth
- Expected 2022 sales approaching \$200M, with 5-year history of strong double-digit growth
- Estimated adjusted EPS* impact: \$0.01 accretive in 2022 and increasingly accretive thereafter

*On a GAAP basis, the transaction is expected to be less accretive, or dilutive as the case may be, in 2022 and less dilutive or increasingly accretive thereafter, as the case may be, due to amortization expense and acquisition-related net charges.



Strategic Rationale



High Sales Synergy


Critical part of EP Ablation, LAAC, and Mitral procedures, currently supported by BSX Sales personnel



Expand US Market Reach

Baylis products are sold in most hospitals with EP and Structural Heart programs

Instantly expands lab access for full suite of BSX EP and Structural Heart solutions



Integrated Solutions

Technology integration opportunity enables strong future product cadence.

Potential workflow enhancements in BSX EP and LAAC procedures



Global Expansion

BSX global footprint accelerates international access and adoption


Commercial and technical synergies drive global growth



Product Overview – Transseptal Needles

Procedure


- Mitral**
- LAAC**
- AFib Ablation**



- ▶ Transseptal puncture (TSP) needles facilitate access to the heart's left side and are used in nearly all catheter-delivered left-heart procedures (most EP ablations, Left Atrial Appendage Closure (LAAC), mitral repair/replace)
- ▶ Precise location of TSP is critical to positioning therapy catheters
- ▶ Two types of needles are used to cross the septum of heart: Traditional (sharp tip) and RF energy (blunt tip)

Baylis Medical


Radiofrequency Tip
Smooth and controlled crossing



- ▶ Baylis' RF needles and wires:
 - Improve safety, ease of use, and enable more precise crossing of the septum
 - Enable fewer access procedural steps
 - Used in ~40% of left-heart procedures today
- ▶ Main competitive solution is sharp tip needle introduced in the 1950s



Baylis Medical Key Products & Solutions



 VersaCross



Latest RF crossing platform that adds efficiency and safety through streamlining workflow and reducing tools required



NRG



More than one million systems sold - Clinically proven to provide safer and more predictable crossing compared to traditional needles



**Sheaths,
dilators and
catheters**



A portfolio of next generation access and mapping solutions to simplify diagnosis and enhance workflows




Market and Portfolio Overview

Expansion of BSX Electrophysiology and Structural Heart Portfolios

Boston Scientific

Baylis MEDICAL

Addressable Market Expansion




■ EP + LAAC + Mitral (excl. Access Solutions)
 ■ Access Solutions

EP Ablations



Access Solutions



LAAC



Mitral



BSX + Baylis:
 Only company to pair comprehensive access portfolio with existing left-heart therapies, adding ~\$1.5B in addressable market to the already fast-growing EP and Structural Heart segments by 2024.



Growth Accretive and Meaningful Strategic Synergies Expected

Category Leadership

Furthers category leadership strategy in left-heart procedures

- Access portfolio complementary to existing BSX EP and Structural Heart portfolios
- Adds global market leader in left-heart access, including novel RF transeptal needles and wires

Attractive Market

Increase exposure to highly attractive end markets

- Weighted-average growth rate of procedures requiring left heart access expected to exceed +10% for many years
- Growing prevalence of arrhythmias; 50M+ people affected by arrhythmias globally
- LAAC global market expected to more than double to \$2B by 2024E

Financially Compelling

Expected to be accretive to BSX's top-line growth and adjusted EPS

- Sales execution synergies with overlapping physician call points for BSX EP and Structural Heart Businesses
- Long-term gross margin expansion due to integration of global supply chain and distribution

WHEN WE CHALLENGE,
WE ADVANCE



**Boston
Scientific**
Advancing science for life™



Baylis Medical Company Acquisition

Thank you